Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 1996

View Archived Issues

Takeda discloses new agents for neurodegenerative disorders

New antioxidant from Shiseido shows CNS activity

New cardiovascular agents claimed by Hoechst

New taxane derivatives from Rhone-Poulenc Rorer

New NO inhibitors disclosed by Fujisawa

Japanese researchers describe orally active antihypertensive agents

Chugai discloses erythromycins for gastrointestinal disorders

Company Profile: Abgenix

Company profile: BioNumerik

Company profile: Corixa

Company profile: Forbes Medi-Tech

Clinical results reported for rhIGF-I in ALS patients

Ebselen on track for NDA filing in Japan

Agreement reached for atorvastatin development in Japan

XOMA receives U.S. patents covering BPI-related products

Water-soluble fiber introduced in first market for high cholesterol

Initial human safety studies completed for CoCensys' stroke drug

Children's Hospital of Philadelphia offers antimicrobial peptides for licensing

Potential drug screening invention available for licensing

Taiho antirheumatic agent possesses novel mechanism of action

Fujisawa antidementia agent in clinical stage

First approval for Aricept

New biochemical marker for Alzheimer's disease identified

FDA clears treatment for bulimia

FDA approves Amphotec

Trinity Biotech obtains license option for hepatitis A antigens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...